标题
FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
作者
关键词
-
出版物
Cells
Volume 10, Issue 4, Pages 884
出版商
MDPI AG
发表日期
2021-04-13
DOI
10.3390/cells10040884
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation
- (2020) Elien Grajchen et al. Journal of Neuroinflammation
- Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis
- (2020) Emanuele D’Amico et al. JOURNAL OF NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis
- (2020) Karl E. Carlström et al. Nature Communications
- Oligodendrocyte Physiology and Pathology Function
- (2020) Markus Kipp Cells
- Oligodendrocyte‐specific deletion of FGFR2 ameliorates MOG 35‐55 ‐induced EAE through ERK and Akt signalling
- (2020) Salar Kamali et al. BRAIN PATHOLOGY
- Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis
- (2019) Yvonne Naegelin et al. JAMA Neurology
- Altered human oligodendrocyte heterogeneity in multiple sclerosis
- (2019) Sarah Jäkel et al. NATURE
- Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives
- (2019) Emanuele D'Amico et al. AUTOIMMUNITY REVIEWS
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
- (2019) Diego Cadavid et al. LANCET NEUROLOGY
- Review: Patient-reported outcomes in multiple sclerosis care
- (2019) Emanuele D'Amico et al. Multiple Sclerosis and Related Disorders
- Microglia Biology: One Century of Evolving Concepts
- (2019) Marco Prinz et al. CELL
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
- (2019) Christina Lückel et al. Nature Communications
- Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential
- (2019) Katja Thümmler et al. Acta Neuropathologica Communications
- Late onset and young onset relapsing remitting multiple sclerosis. Evidence from a retrospective long-term follow-up study
- (2018) Emanuele D'Amico et al. EUROPEAN JOURNAL OF NEUROLOGY
- Role of mitochondrial ROS in the brain: from physiology to neurodegeneration
- (2018) Plamena R. Angelova et al. FEBS LETTERS
- Multiple sclerosis
- (2018) Alan J Thompson et al. LANCET
- Multiple Sclerosis
- (2018) Daniel S. Reich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Sclerosis Pathology
- (2018) Hans Lassmann Cold Spring Harbor Perspectives in Medicine
- Glia-neuron energy metabolism in health and diseases: New insights into the role of nervous system metabolic transporters
- (2018) Mithilesh Kumar Jha et al. EXPERIMENTAL NEUROLOGY
- Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab
- (2018) Jennifer Petrillo et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- How Do Cells of the Oligodendrocyte Lineage Affect Neuronal Circuits to Influence Motor Function, Memory and Mood?
- (2018) Renee E. Pepper et al. Frontiers in Cellular Neuroscience
- Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience
- (2018) Emanuele D'Amico et al. Multiple Sclerosis and Related Disorders
- Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2–MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner
- (2017) Miki Furusho et al. JOURNAL OF NEUROSCIENCE
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
- (2017) Diego Cadavid et al. LANCET NEUROLOGY
- New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany
- (2017) Peter Flachenecker et al. Multiple Sclerosis Journal
- Regenerating CNS myelin — from mechanisms to experimental medicines
- (2017) Robin J. M. Franklin et al. NATURE REVIEWS NEUROSCIENCE
- Assessing association of comorbidities with treatment choice and persistence in MS
- (2017) Alice Laroni et al. NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany
- (2017) Peter Flachenecker et al. Multiple Sclerosis Journal
- Multiple sclerosis: experimental models and reality
- (2016) Hans Lassmann et al. ACTA NEUROPATHOLOGICA
- Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs
- (2016) Emanuele D’Amico et al. DRUG SAFETY
- The role of growth factors as a therapeutic approach to demyelinating disease
- (2016) Yangyang Huang et al. EXPERIMENTAL NEUROLOGY
- Antiglutamatergic therapy for multiple sclerosis?
- (2016) Reinhard Hohlfeld et al. LANCET NEUROLOGY
- Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal
- (2016) Emanuele D’Amico et al. Multiple Sclerosis Journal
- Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis
- (2016) Tomas Olsson et al. Nature Reviews Neurology
- Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal
- (2016) Emanuele D’Amico et al. Multiple Sclerosis Journal
- Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9
- (2015) Maren Lindner et al. BRAIN
- Distinct sets of FGF receptors sculpt excitatory and inhibitory synaptogenesis
- (2015) A. Dabrowski et al. DEVELOPMENT
- Fibroblast growth factor signaling in oligodendrocyte-lineage cells facilitates recovery of chronically demyelinated lesions but is redundant in acute lesions
- (2015) Miki Furusho et al. GLIA
- Inefficient clearance of myelin debris by microglia impairs remyelinating processes
- (2015) Antoine Lampron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Role of the innate and adaptive immune responses in the course of multiple sclerosis
- (2015) Bernhard Hemmer et al. LANCET NEUROLOGY
- Exploring the origins of grey matter damage in multiple sclerosis
- (2015) Massimiliano Calabrese et al. NATURE REVIEWS NEUROSCIENCE
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Revised diagnostic criteria of multiple sclerosis
- (2014) Ron Milo et al. AUTOIMMUNITY REVIEWS
- Mechanisms of white matter damage in multiple sclerosis
- (2014) Hans Lassmann GLIA
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination
- (2014) Hema Mohan et al. Acta Neuropathologica Communications
- Fibroblast Growth Factor-2 Signaling in Neurogenesis and Neurodegeneration
- (2013) Maya E. Woodbury et al. Journal of Neuroimmune Pharmacology
- FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination
- (2013) Amanda J. Mierzwa et al. NEUROSCIENCE LETTERS
- The mechanism of action of glatiramer acetate in multiple sclerosis and beyond
- (2012) Rina Aharoni AUTOIMMUNITY REVIEWS
- Rejuvenation of Regeneration in the Aging Central Nervous System
- (2012) Julia M. Ruckh et al. Cell Stem Cell
- Fibroblast Growth Factor Receptor Signaling in Oligodendrocytes Regulates Myelin Sheath Thickness
- (2012) M. Furusho et al. JOURNAL OF NEUROSCIENCE
- Neuroprotection and repair in multiple sclerosis
- (2012) Robin J. M. Franklin et al. Nature Reviews Neurology
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capture, crawl, cross: the T cell code to breach the blood–brain barriers
- (2012) Britta Engelhardt et al. TRENDS IN IMMUNOLOGY
- Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis
- (2011) F. Patti et al. ACTA NEUROLOGICA SCANDINAVICA
- Enhancing remyelination in disease--can we wrap it up?
- (2011) M. R. Kotter et al. BRAIN
- Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
- (2011) Cris S Constantinescu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications
- (2011) Christine Stadelmann CURRENT OPINION IN NEUROLOGY
- Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study
- (2011) M. H. Harirchian et al. EUROPEAN JOURNAL OF NEUROLOGY
- Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis
- (2011) Andrea Rottlaender et al. IMMUNOLOGY
- FGF-2 and Anosmin-1 Are Selectively Expressed in Different Types of Multiple Sclerosis Lesions
- (2011) D. Clemente et al. JOURNAL OF NEUROSCIENCE
- Fibroblast Growth Factor Signaling Is Required for the Generation of Oligodendrocyte Progenitors from the Embryonic Forebrain
- (2011) M. Furusho et al. JOURNAL OF NEUROSCIENCE
- Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords
- (2010) Géraldine Androdias et al. ANNALS OF NEUROLOGY
- Evidence for a two-stage disability progression in multiple sclerosis
- (2010) E. Leray et al. BRAIN
- Treatment options of cognitive impairment in multiple sclerosis
- (2010) Francesco Patti et al. NEUROLOGICAL SCIENCES
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Animal models of multiple sclerosis—Potentials and limitations
- (2010) Eilhard Mix et al. PROGRESS IN NEUROBIOLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- The relation between inflammation and neurodegeneration in multiple sclerosis brains
- (2009) Josa M. Frischer et al. BRAIN
- Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
- (2009) Bruce D Trapp et al. LANCET NEUROLOGY
- Remyelination protects axons from demyelination-associated axon degeneration
- (2008) K. A. Irvine et al. BRAIN
- Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis
- (2008) T. Kuhlmann et al. BRAIN
- The biology of CNS remyelination
- (2008) Robin J. M. Franklin et al. JOURNAL OF NEUROLOGY
- Remyelination in the CNS: from biology to therapy
- (2008) Robin J. M. Franklin et al. NATURE REVIEWS NEUROSCIENCE
- Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients
- (2008) Paola Sarchielli et al. NEUROSCIENCE LETTERS
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now